Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 27;11:594152. doi: 10.3389/fneur.2020.594152

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Fan, Li, Shen, Zhang, Lei, Su, Lu, Di, Wang, Xu and Da.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Therapeutic effects of tacrolimus monotherapy. (A,B) Therapeutic effects in all patients were evaluated by changes in MG-ADL scores (A) and by changes in QMG scores (B). (C,D) Therapeutic effects in subgroups of OMG and GMG were evaluated by changes in MG-ADL (C) and by changes in QMG scores (D). The effect was the mean difference of MG-ADL or QMG scores during the follow-up periods. Statistical analysis was performed by linear mixed model for repeated measurements with Bonferroni correction. QMG, quantitative myasthenia gravis score; MG-ADL, myasthenia gravis activities of daily living; OMG, ocular myasthenia gravis; GMG, generalized myasthenia gravis.